Ohyashiki J H, Ohyashiki K, Aizawa S, Kawakubo K, Shimamoto T, Iwama H, Hayashi S, Toyama K
First Department of Internal Medicine, Tokyo Medical College, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160, Japan.
Clin Cancer Res. 1996 Sep;2(9):1583-9.
Genetic alteration, including genomic instability, is an ultimate step toward the malignant process. One approach to delineating replication errors in cancer cells is to determine the alterations of microsatellites, which are short, repeated nucleotide sequences existing throughout the genomes. We used a fluorescent system to assess microsatellite changes in seven loci (D2S123, D3S643, D5S107, LPL, D17S261, TP53, and D18S34) of 73 consecutive patients with various hematological neoplasias. De novo acute leukemia patients had a low frequency (<1%) of microsatellite alterations at each locus, and none of them demonstrated multiple microsatellite changes. In chronic myeloid leukemia patients, no microsatellite instability was detected in the chronic phase, whereas a relatively high frequency (25%) of multiple microsatellite changes was evident in the blastic phase, and half of these patients had multiple microsatellite changes. About 50% of the patients with myelodysplastic syndrome (MDS) and post-MDS acute myeloid leukemia (post-MDS AML) had microsatellite alterations. We next compared microsatellite alterations in two different hematological phases (MDS and post-MDS AML phases); 5 of 11 patients with post-MDS AML had de novo appearance of microsatellite instability during disease progression. This indicates that genomic instability at multiple microsatellite loci could occur either before or after leukemic transformation in MDS patients. We concluded that genomic instability in chronic myeloid leukemia might be linked to blastic transformation in combination with cytogenetic changes. In contrast, MDS patients had replication errors as a relatively early genetic event as well as a late genetic event. These results suggest that the involvement of genomic instability in the progression of disease is different among various types of leukemia.
基因改变,包括基因组不稳定,是走向恶性过程的最终步骤。描绘癌细胞复制错误的一种方法是确定微卫星的改变,微卫星是存在于整个基因组中的短的重复核苷酸序列。我们使用荧光系统评估了73例连续的各种血液系统肿瘤患者的7个位点(D2S123、D3S643、D5S107、LPL、D17S261、TP53和D18S34)的微卫星变化。初发急性白血病患者每个位点的微卫星改变频率较低(<1%),且无一例表现出多个微卫星变化。在慢性髓性白血病患者中,慢性期未检测到微卫星不稳定,而在急变期多个微卫星变化的频率相对较高(25%),且这些患者中有一半有多个微卫星变化。约50%的骨髓增生异常综合征(MDS)和MDS后急性髓性白血病(MDS后AML)患者有微卫星改变。接下来,我们比较了两个不同血液学阶段(MDS和MDS后AML阶段)的微卫星改变;11例MDS后AML患者中有5例在疾病进展过程中出现了微卫星不稳定的新发情况。这表明MDS患者在白血病转化之前或之后都可能发生多个微卫星位点的基因组不稳定。我们得出结论,慢性髓性白血病中的基因组不稳定可能与细胞遗传学改变相结合的急变有关。相比之下,MDS患者的复制错误既是相对早期的遗传事件,也是晚期的遗传事件。这些结果表明,基因组不稳定在不同类型白血病疾病进展中的参与情况有所不同。